|
Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
Niraj Niraj1, Sonia Shinde Mahajan2, Ajay Prakash1, Phulen Sarma1, Bikash Medhi1
1 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Pharmacology, All India Institute of Medical Sciences, Jammu, Jammu and Kashmir, India
Correspondence Address:
Bikash Medhi
Department of Pharmacology, Research Block B, 4th Floor, Room No 4043, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India
Coronavirus infection is a pandemic threat and the most dangerous disease of the 21st century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease.
How to cite this article:
Niraj N, Mahajan SS, Prakash A, Sarma P, Medhi B. Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era.Indian J Pharmacol 2022;54:452-458
|
How to cite this URL:
Niraj N, Mahajan SS, Prakash A, Sarma P, Medhi B. Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era. Indian J Pharmacol [serial online] 2022 [cited 2023 Jun 8 ];54:452-458
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2022;volume=54;issue=6;spage=452;epage=458;aulast=Niraj;type=0 |
|
